The Efficacy And Safety Of Roxadustat In The Treatment Of Renal Anemia In Maintenance Dialysis Patients

Objective: To observe the efficacy and safety of Roxadustat in the treatment of renal anemia in maintenance dialysis patients.Methods: Screen patients with maintenance dialysis who were regularly followed up with renal anemia treatment in the Dialysis Center of the First Affiliated Hospital of China Medical University from October 2019 to June 2020,switched from regular using erythropoiesis stimulants to oral hypoxia induction Factor-prolyl hydroxylase inhibitor--Roxadustat.Observe the effects of hemoglobin,ferritin,transferrin,changes in blood lipids and the effect of Roxadustat on hemoglobin in patients with inflammation indexes and evaluate its safety.Results: 1.There were 31 dialysis patients in the study,22 males and 9 females.There were 11 hemodialysis patients and 20 peritoneal dialysis patients.The initial hemoglobin level during the application of recombinant human erythropoietin was 83.54±13.21g/L,and the hemoglobin level of Roxadustat for 3 months was 103.97±15.72 g/L,the difference was statistically significant(P=0.007).After 3 months,the hemoglobin of the patients increased by an average of 21.35±11.28 g/L,and after 6 months,the hemoglobin of the patients increased by 20.68±14.89 g/L on average.There were 12 patients whose hemoglobin reached the standard(Hb>110g/l),and the compliance rate was 38.7%.Among them,9 peritoneal dialysis patients had hemoglobin compliance,with a compliance rate of 45%.The hemoglobin of 3 hemodialysis patients reached the standard,and the compliance rate was 27.3%.2.The ferritin level during the treatment period of Roxadustat has decreased by 72.52±162.77 ug/L,and the difference is statistically significant(P=0.019).The change of serum iron was not significant,and the difference was statistically noninferior(P=0.081).The transferrin level increased by 25.29±48.7mg/dl,the difference was statistically significant(P<0.01),the transferrin saturation was statistically noninferior(P=0.201).3.the level of total cholesterol,low-density and high-density lipoprotein cholesterol were reduced by Roxadustat.5.In 18 patients with high C-reactive protein,the average CRP level was 19.90±15.44mg/L.However,during the application of Roxadustat,the hemoglobin level still increased.The application of Roxadustat phase resulted in an increase in hemoglobin level of 21.06±15.56 g/L compared to the application of recombinant human erythropoietin.5.No obvious adverse reactions occurred during the application of Roxadustat.Conclusion: Roxadustat was effective in treating renal anemia in dialysis patients,and improved the hemoglobin compliance rate of patients who not met the standard treatment with traditional erythropoiesis stimulants.Roxadustat was not susceptible to inflammatory indicators in the treatment of renal anemia.It could improve iron intake and might increase iron utilization.Roxadustat was relatively safe to take orally...